{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:41Z","timestamp":1786120361485,"version":"build-2736575974"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/ico.0b013e31823f8d71","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T05:50:32Z","timestamp":1329889832000},"page":"937-944","source":"Crossref","is-referenced-by-count":23,"title":["Effects of Subconjunctival Bevacizumab on Corneal Neovascularization"],"prefix":"10.1097","volume":"31","author":[{"given":"Yohan","family":"Benayoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Adenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Casse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimondo","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":". Corneal neovascularization.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R2-17-20210204","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.preteyeres.2010.01.002","article-title":". Novel aspects of corneal angiogenic and lymphangiogenic privilege.","volume":"29","author":"Ellenberg","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"R3-17-20210204","doi-asserted-by":"crossref","first-page":"11405","DOI":"10.1073\/pnas.0506112103","article-title":". Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.","volume":"103","author":"Cursiefen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R4-17-20210204","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/eye.2009.72","article-title":". The influence of donor and recipient factors in allograft rejection of the human cornea.","volume":"24","author":"Rahman","year":"2000","journal-title":"Eye (Lond)"},{"key":"R5-17-20210204","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R6-17-20210204","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1128\/JVI.75.20.9828-9835.2001","article-title":". Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.","volume":"75","author":"Zheng","year":"2001","journal-title":"J Virol"},{"key":"R7-17-20210204","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/emboj\/19.7.1525","article-title":". Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.","volume":"19","author":"Binetruy-Tournaire","year":"2000","journal-title":"EMBO J"},{"key":"R8-17-20210204","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s004320050283","article-title":". Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor.","volume":"125","author":"Schlaeppi","year":"1999","journal-title":"J Cancer Res Clin Oncol"},{"key":"R9-17-20210204","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":". Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R10-17-20210204","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","article-title":"Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome.","volume":"27","author":"Uy","year":"2008","journal-title":"Cornea"},{"key":"R11-17-20210204","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":". Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"R12-17-20210204","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R14-17-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2006.02.037","article-title":". Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.","volume":"142","author":"Bashshur","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R16-17-20210204","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.","volume":"26","author":"Avery","year":"2006","journal-title":"Retina"},{"key":"R17-17-20210204","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"R18-17-20210204","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":". Safety profile of bevacizumab on cultured human corneal cells.","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"R19-17-20210204","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1167\/iovs.07-1129","article-title":". Safety profile of topical VEGF neutralization at the cornea.","volume":"50","author":"Bock","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-17-20210204","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/ICO.0b013e31818b8be0","article-title":". Evaluation of cytotoxic effects of bevacizumab on human corneal cells.","volume":"28","author":"Shalam","year":"2009","journal-title":"Cornea"},{"key":"R21-17-20210204","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R22-17-20210204","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","article-title":"Subconjunctival bevacizumab for vascularized rejected corneal grafts.","volume":"33","author":"Awadein","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"R23-17-20210204","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":". Subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"R24-17-20210204","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.ico.0000611440.32234.8f","article-title":"Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.","volume":"27","author":"Carrasco","year":"2008","journal-title":"Cornea"},{"key":"R25-17-20210204","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"},{"key":"R26-17-20210204","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/ICO.0b013e31817c41e3","article-title":". Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Qian","year":"2008","journal-title":"Cornea"},{"key":"R27-17-20210204","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":". Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R28-17-20210204","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00417-009-1170-y","article-title":"Avastin use in high risk corneal transplantation.","volume":"247","author":"Vassileva","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R29-17-20210204","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/ICO.0b013e31819839f9","article-title":"Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.","volume":"28","author":"Oh","year":"2009","journal-title":"Cornea"},{"key":"R30-17-20210204","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1755-3768.2009.01585.x","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"88","author":"Zaki","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R31-17-20210204","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization.","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R32-17-20210204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":". Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R33-17-20210204","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":". Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R34-17-20210204","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":". Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R35-17-20210204","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":". The effect of topical bevacizumab on corneal neovascularization.","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R36-17-20210204","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/ICO.0b013e3181861cc9","article-title":"Bevacizumab (avastin) for corneal neovascularizationcorneal light shield soaked application.","volume":"28","author":"Mackenzie","year":"2009","journal-title":"Cornea"},{"key":"R37-17-20210204","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.exer.2008.08.007","article-title":". Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts.","volume":"87","author":"Bock","year":"2008","journal-title":"Exp Eye Res"},{"key":"R38-17-20210204","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ophtha.2009.04.016","article-title":". GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.","volume":"116","author":"Cursiefen","year":"2009","journal-title":"Ophthalmology"},{"key":"R39-17-20210204","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1167\/iovs.09-3745","article-title":". Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.","volume":"51","author":"Dastjerdi","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R40-17-20210204","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":". Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R41-17-20210204","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-0420.2007.01057.x","article-title":". Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.","volume":"86","author":"Soliman","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R42-17-20210204","first-page":"130","article-title":"Kurzrock R, et al..","volume":"15","author":"Vaklavas","year":"2010","journal-title":"Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target Oncologist"},{"key":"R43-17-20210204","first-page":"1112","article-title":"Correlation of VEGF expression by leucocytes with the growth and regression of blood vessels in the rat cornea.","volume":"40","author":"Edelman","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R44-17-20210204","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-9071.2007.01572.x","article-title":". Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.","volume":"35","author":"Hosseini","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"R45-17-20210204","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11373-007-9153-7","article-title":"Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model.","volume":"14","author":"Lai","year":"2007","journal-title":"J Biomed Sci"},{"key":"R46-17-20210204","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","article-title":". Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R47-17-20210204","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1167\/iovs.07-1418","article-title":". Vascular endothelial growth factor mediates corneal nerve repair.","volume":"49","author":"Yu","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"suppl 1","key":"R48-17-20210204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.9-suppl_1-11","article-title":"Targeted therapy of colorectal cancer: clinical experience with bevacizumab.","volume":"9","author":"Fernando","year":"2004","journal-title":"Oncologist"},{"key":"R49-17-20210204","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0420.2006.00819.x","article-title":"Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.","volume":"85","author":"Kernt","year":"2007","journal-title":"Acta Ophthalmol Scand"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003226-201208000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:36:45Z","timestamp":1786048605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201208000-00017"}},"subtitle":["Results of a Prospective Study"],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31823f8d71","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}